Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q1 2025 Earnings Presentation
16 slides from Q-linea Ab's earnings presentation, Apr 14, 2025
Slide 1: 2025 Q1 Report
Sustainable healthcare for a new generation 2025 Q1 Report April 14, 2025
Slide 2: Disclaimer
Disclaimer THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. T
Slide 3: Topics for today
❖ Commercial progress Topics for ❖ Market outlook for 2025 and beyond today ❖ Financial update ❖ Respond to your questions
Slide 4: Key messages for today
Key messages for today 1 Q1 commercial activity surpassed full-year 2024 with five contracts signed during the quarter Installations running smoothly with three ASTars installed in Q1, 2 raising total to seven ASTars in routine clinical use 3 Meeting plan on revenue and cost with 20% YoY reduction i
Slide 5: ASTar: Revolutionizing AST
ASTar: Revolutionizing AST ~6 ~2 1st Hours Minutes Fully-automated, turn-around time Hands-on time random access platform ➢ Save lives ➢ Simple interface ➢ Comprehensive menu ➢ Save money ➢ Load-and-Go ➢ High reproducibility ➢ Reduces clinical effort ➢ Minimal training need ➢ High throughput with 12
Slide 6: Gaining momentum | Q1 contracts more than double ASTar installed base
Gaining momentum | Q1 contracts more than double ASTar installed base ASTar units contracted for routine clinical use at end-of-period ❖ Three contracts signed in US market 30 – 40 ❖ Including Master Service Agreement with major US national reference lab network ❖ Belgian tender won : first ASTar in
Slide 7: Pipeline expansion | Focused on accelerating cycle time from evaluation to go-live
Pipeline expansion | Focused on accelerating cycle time from evaluation to go-live 4 – 6 mths 3 – 6 mths 2 – 6 mths 1– 3 mths INITIAL CUSTOMER CUSTOMER DEMO PURCHASE PROCESS INSTALL & GO LIVE ROUTINE USE ENGAGEMENT & EVALUATION & NEGOTIATION • Lab planning & training • Aftermarket service & • Q-line
Slide 8: Recap | Building a $600 – 900 million market segment for blood stream infection testing
Recap | Building a $600 – 900 million market segment for blood stream infection testing Current Standard-of-Care Emerging Gold Standard Future potential technologies Informational (rapid AST) value 5 – 7m blood stream infection ❖ $120 – 180 per test tests Clinically- ❖ $600 – 900m market for 5 – 10m
Slide 9: Live from Vienna | ESCMID conference ongoing
Live from Vienna | ESCMID conference ongoing ❖ Q-linea and ASTar prominent as leading solution for rapid AST ❖ Dozens of customer leads, evaluation requests and further distribution opportunities ❖ Q-linea presented three research posters: importance of controlled inoculum, gram-positive performance
Slide 10: Update | Status against our ambition for the year
Update | Status against our ambition for the year Commercial Progress Clinical Progress Financial Progress ✓ Increasing pace of contracted units ❖ Mounting clinical evidence ❖ Funding 2024 ≤ Q1 ≤ Q2 ≤ Q3 … ✓ LIFETIMES study LPI (last ✓ Rights issue complete (Jan) ✓ First multi-site contract signed (
Slide 11: Financial highlights | First quarter 2025
Financial highlights | First quarter 2025 REVENUES Net sales SEK 3.7 million for the quarter, approx. 250% growth over Q1 2024 and already higher than FY 2024 Recurring income from consumables will continue to increase as the installed base increases Development in line with our financial plan to br
Slide 12: OPEX development | 2023 – 2025Q1
OPEX development | 2023 – 2025Q1 ❖ Cost program implemented during Q2 delivered approx. Personnel expenses + Other external costs SEK 4 million per month in savings (approx. SEK 50 25 000 million annually) 20 000 ❖ Additional efficiencies and avoided costs resulting in 15 000 further SEK 10 million
Slide 13: Events to come | April - July
Events to come| April - July ❖ Price setting period for subscription via warrants: 14 – 29 April ❖ Annual report will be published 25 April ❖ Subscription period of shares with support of warrants: 5 – 19 May ❖ AGM 26 June (reversed split of shares, details to be published later) ❖ Q2 interim report
Slide 14: Funding | Share issue with support/use of warrants
Funding | Share issue with support/use of warrants MSEK Subscription (%) Share price (öre) 10 20 30 40 50 60 70 80 90 100 15 22 44 66 89 111 133 155 177 199 222 ❖ Amount depends on share price and 14 21 41 62 83 103 124 145 165 186 207 subscripton rate 13 19 38 58 77 96 115 134 154 173 192 12 18 35
Slide 15: Future financing
Future financing ❖ Secured financing: Cash at hand 31 of March 2025: SEK 68.0 million ❖ Additional sources of financing anticipated Second part of rights issue – warrants: Depends on share price and subscription level Non-dilutive financing (Grants) Actively seeking Licencing of technology Ongoing d
Slide 16: Thank you!
Thank Questions? you!